Efficacy of magnesium isoglycyrrhizinate in treatment of hepatitis E with severe jaundice

Objective To observe and analyze the efficacy of magnesium isoglycyrrhizinate in the treatment of hepatitis E with severe jaundice. Methods Seventy- eight cases of hepatitis E with severe jaundice admitted from January 2009 to December 2012 were equally divided into treatment group ( n = 39) and control group ( n = 39) . Both groups were given polyene phosphatidylcholine, reduced glutathione, and Adenosine Disodiu for liver protection; additionally, magnesium isoglycyrrhizinate injection ( 150 mg) was given to the treatment group by intravenous drip once daily, while compound glycyrrhizin injection ( 120 mg) was given to the control group by intravenous drip once daily. The course of treatment was 6 weeks in the two groups. Patients were considered to show response to treatment if their serum levels of total bilirubin ( TBil) and alanine aminotransferase were < 85 μmol /L and < 160 U /L, respectively. Comparison of means between the two groups was made by independent- samples t test; before- after comparison within each group was made by paired t- test; comparison of enumeration data between the two groups was made by chi- square test. Results Both groups showed improvements after treatment. The treatment group had a significantly higher overall response rate than the control group ( 84. 6% vs 66. 7%, P < 0. 05) . After treatment, the treatment group had a serum TBil level of 68. 9 ± 40. 3 μmol /L, with significantly more improvement compared with the serum TBil level for control group ( 129. 1 ± 69. 3 μmol /L) ( F = 24. 658, χ2= 12, P < 0. 01; F = 36. 145, χ2= 15, P < 0. 01) . Conclusion Magnesium isoglycyrrhizinate has significant efficacy in the treatment of hepatitis E with severe jaundice. It shows a marked promotional effect on the proliferation of liver cells within a certain concentration range, accelerates jaundice disappearance, and has no obvious adverse effects.